This episode covers crucial regulatory developments involving deceptive earnings claims in multi-level marketing, updates from the SEC on equity and options trade reporting, and important product safety recalls related to hazardous substances. Additionally, listeners will learn about new FDA inspection programs for biological product manufacturers.

The Federal Trade Commission has issued a permanent order against Forever Living and its operators for deceptive earnings claims, requiring substantiation for any earnings statements and banning misrepresentations. In parallel, the FTC settled enforcement actions against Stormy Wellington, mandating strict adherence to truthful earnings disclosures.

The Securities and Exchange Commission released a concept proposal addressing governance and technology challenges for the Consolidated Audit Trail system, inviting public comment on potential restructuring. The SEC also announced a regional compliance seminar focusing on fiduciary standards and examination priorities for investment advisers and companies.

A product recall was initiated for a nail polish remover containing methylene chloride and chloroform due to serious health risks, with consumers urged to safely dispose of affected products. Furthermore, the FDA rolled out a structured compliance program for prelicense and preapproval inspections of biological product manufacturers to ensure product safety and regulatory compliance.

For more information, visit the Carver Agents website.

Articles mentioned:

1. FTC Order to Prohibit Forever Living and its Operators from Deceiving Consumers about Potential Earnings
2. Cattywampus: Statement on the CAT Concept Release
3. US and UK Regulators Warn Banks of AI Model Mythos' Cybersecurity Risks
4. FTC Takes Action Against High-Level MLM Participant who Deceived Workers About the Amount of Money They Can Earn
5. FCC Reminder to Debris Removal & Utility Repair Teams
6. DE-1
7. Product Recall
8. FTC Testifies Before Senate Commerce, Science and Transportation Committee
9. Prelicense and Preapproval Inspections of CDER-Regulated Biological Product Manufacturers (7346.832M)
10. 2026 Compliance Outreach Program Regional Seminar for Investment Advisers and Investment Companies (New York)